Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 50,819

Document Document Title
WO/2018/188635A1
A cerasome delivery system for use in the targeted activation of a CD44 molecule, a preparation method and use thereof: a surface of a cerasome is partially modified by a targeting ligand, the targeting ligand being a ligand which may sp...  
WO/2018/189559A1
The present invention concerns the antiplatelet activity of Acanthus mollis seeds' methanolic extract and the identification of its constituents responsible for this effect, using the techniques LTA, NMR, HPLC and LC-MS, respectively. We...  
WO/2018/186322A1
The present invention provides anti-MASP-1 (mannan-binding lectin (MBL)-associated serine protease 1) antibodies and methods of using the same. In some embodiments, an anti-MASP-1 antibody of the invention binds to MASP-1 but does not bi...  
WO/2018/187493A1
Compositions and methods for fetal or in utero delivery of active agents are provided. The compositions are most typically administered intravenously via the vitelline vein, umbilical vein, or directly into the amniotic cavity of a pregn...  
WO/2018/181987A1
Provided is an adsorbent for indole and derivatives thereof that selectively adsorbs indole and derivatives thereof (particularly indole). A copolymer synthesized by mixing structural units based on each monomer at an optimal ratio was d...  
WO/2018/181380A1
To provide an edible composition for intestinal bacteria which ameliorates intestinal flora (intestinal bacterial flora) and promotes the diversity thereof so as to contribute to human health. A composition comprising: a natural dietary ...  
WO/2018/178141A1
The present invention is directed to a crystalline sodium salt of 5-methyl-(6S)- tetrahydrofolic acid wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to sodium is from 1:0.5 to 1:1.5 (in mol/mol) and/or hydrates and/or solv...  
WO/2018/181870A1
The present inventors verified the coagulation promoting effect of multispecific antigen binding molecules, said molecules replacing the function of FVIII, using blood and plasma collected from patients with FIX abnormality. As a result,...  
WO/2018/178142A1
The present invention is directed to crystalline salt of 5-methyl-(6S)-tetrahydrofolic acid comprising (i) 5-methyl-(6S)-tetrahydrofolic acid, (ii) sodium and (iii) an organic base having a pKa value from 6 to 11; wherein the molar ratio...  
WO/2018/177993A1
The invention relates, inter alia, to compounds of general formula (I). The invention also relates to methods for synthesizing the compounds of formula (I). The compounds according to the invention are in particular suitable for controll...  
WO/2018/179974A1
A sterilized peritoneal dialysis solution that comprises an acidic first solution containing icodextrin and a second solution containing 300-3,000 mg/L of L-histidine and a pH controller, wherein: the first solution contains no pH contro...  
WO/2018/178144A1
The present invention is directed to a crystalline sodium salt of 5-methyl-(6S)- tetrahydrofolic acid wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to sodium is from 1:1.51 to 1:2.5 and/or hydrates and/or solvates thereof...  
WO/2018/181071A1
The present invention addresses the problem of providing an agent for degrading a non-collagenous glycoprotein, a composition for degrading a non-collagenous glycoprotein, a medicinal composition for degrading a non-collagenous glycoprot...  
WO/2018/170568A1
The invention falls within the fields of biochemistry, molecular biology, genetics, pharmacy and medicinal chemistry, being related to biochemical and metabolic processes. More specifically, the present invention provides a novel class o...  
WO/2018/175474A1
The disclosure relates to modulating pyruvate kinase and provides novel chemical compounds of formula (I) useful as activators of PKR, as well as various uses of these compounds. PKR activating compounds are useful in the treatment of di...  
WO/2018/171004A1
Provided are a class of compounds, which have an anti-platelet aggregation activity, of general formula I and a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition and use thereof. Th...  
WO/2018/172129A1
The invention relates to sialic acid derivatives of formula (I) which contain a C-C triple bond, methods for the preparation thereof, conjugates produced therefrom and drugs containing same, wherein the symbols have the meanings defined ...  
WO/2018/168407A1
Provided are: a composition for inhibiting the growth of a bacterium having a menaquinone synthesis pathway through futalosine or a futalosine derivative, said composition comprising as an active ingredient a fatty acid which carries 18 ...  
WO/2018/170335A1
The present disclosure provides distinct therapeutic populations of cells that form a pharmaceutical composition useful in hematopoietic stem/progenitor cell transplant. For example, the present disclosure provides a therapeutic populati...  
WO/2018/167119A1
Thrombosis is the main cause of morbidity and mortality in patients with JAK2V617F positive myeloproliferative neoplasms (MPN). Recent works reported the presence of JAK2V617F in endothelial cells in some MPN patients. Here, the inventor...  
WO/2018/169055A1
It is known that foods containing a carbohydrate, e.g., starch, in a large amount generate acrylamide upon heating at high temperatures. Some documents state that acrylamide is formed by the Maillard reaction of an amino acid, e.g., aspa...  
WO/2018/169061A1
The present invention addresses the problem of providing a method for efficiently separating megakaryocytes from platelets produced from the megakaryocytes, and of providing an instrument for efficiently separating megakaryocytes from pl...  
WO/2018/167287A1
The invention relates to the field of treatment or prevention of obesity-related disorders, atherosclerosis or a coagulation disorder. In particular, the present invention relates to the use of an activator of IFN╬╗ receptor for the trea...  
WO/2018/167139A1
The present invention relates to a P2Y12 receptor antagonist selected from the group consisting of4-((R)-2-{[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyri midine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine- 1-carboxylic acid b...  
WO/2018/169554A1
The present invention relates to methods, systems, factors, and media for the reduction of cellular stress and reduction of the amount reactive oxygen species. Embodiments of the invention reduce cellular stress by treating cells with a ...  
WO/2018/164186A1
The present invention provides: a nucleic acid having an activity to inhibit the expression of MASP2; a pharmaceutical composition containing the nucleic acid; and a prophylactic or therapeutic agent for autoimmune diseases including APS...  
WO/2018/165495A1
Disclosed herein are compositions including cyclodextrin and Nle3-A(1 -7) [Asp-Arg- Me-Tyr-Ile-His-Pro (SEQ ID NO: l)] and their use in treating various disorders.  
WO/2018/162426A1
The present invention relates to the treatment and the diagnosis of the hereditary xerocytosis (HX). The inventors showed that in case of HX due to mutations in PIEZO1, KCNN4 activation is responsible for erythrocyte dehydration, and tha...  
WO/2018/160154A1
The invention relates to a lotion composed of individuals or combinations of compounds selected from a group consisting of acid, iron oxide, water, oil, surfactant for treatment of diseases arising from iron deficiency.  
WO/2018/159580A1
The present invention provides pentosan polysulfate having a weight average molecular weight of 5000 or less and an acetyl group content of 0-2.0 mass% or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solva...  
WO/2018/159604A1
The present invention relates to a novel conjugate of heparin and polyamine, an anticoagulant comprising the conjugate, a pharmaceutical composition containing the conjugate, a kit for producing the conjugate, a sustained release agent, ...  
WO/2018/155435A1
The present invention provides a granular preparation which has an improved feel of ingestion and comprises isoleucine, leucine and valine. The present invention relates to a granular preparation comprising isoleucine, leucine and valine...  
WO/2018/154161A1
Pharmaceutical composition comprising 2,5-dihydroxybenzenesulfonic acid or a pharmaceutically acceptable salt thereof in the form of personalised supply units and the corresponding manufacturing method. Pharmaceutical composition compris...  
WO/2018/155457A1
Provided is an immunogenic composition that comprises a carrier protein and an immunogenic peptide for inducing production of a neutralizing antibody against S100A9. Said immunogenic composition has an antithrombotic effect, can be used ...  
WO/2018/154530A1
Pharmaceutical and nutritional composition comprising maltol and/or ethyl maltol for use in the therapy of iron deficiency (ID) and ID-anemia (IDA). The iron-free composition produce an efficient extraction of dietary non-heme iron from ...  
WO/2018/151239A1
The present invention addresses the problem of providing an acid-sensing ion channel inhibitor which is orally administrable. The solution of the present invention is a compound represented by formula (I) or a pharmaceutically acceptable...  
WO/2018/150066A1
The present invention relates to the use of modulators that inhibit the function of the CD69 molecule, preferably an anti-CD69 antibody, to prepare a medicinal drug that causes the proliferation and output or mobilisation of haematopoiet...  
WO/2018/151243A1
Provided is a red blood cell protective agent that allows for longer-term storage and safer use of a red blood cell-containing solution (e.g., red blood cell concentrate). When red blood cells are stored for a long period of time, phosph...  
WO/2018/149309A1
The present invention provides a crystal form of a 4-phenylthiazole derivative, a pharmaceutical composition comprising the same, a preparation method, and a use of the crystal form in preparing a drug for treating thrombocytopenia assoc...  
WO/2018/151184A1
The purpose of the present invention is to provide a novel composition for preventing or improving anemia. The present invention provides a composition for preventing or improving anemia, the composition comprising a mineral component as...  
WO/2018/146235A1
The invention pertains to a blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings of patients having an acquired coagulation factor deficiency or for use in the treatment or prophylaxis of blee...  
WO/2018/145364A1
The present invention provides use of 3,4,7-trihydroxyisoflavone or 3-methoxy daidzein in the preparation of medicaments for inhibiting platelet aggregation, the 3,4,7-trihydroxyisoflavone having a structure as represented by formula I, ...  
WO/2018/145533A1
An antibody combined with coagulation factor XI (FXI) and/or an activated factor thereof XIa (FXIa), or a fragment of FXI and/or FXIa, and a composition comprising the antibody. Further disclosed are a method for preparing the antibody, ...  
WO/2018/142364A1
The present invention is directed to genome editing systems, reagents and methods for the treatment of hemoglobinopathies.  
WO/2018/141863A1
The present invention relates to improved procoagulant antibodies including bispecific antibodies capable of binding to coagulation Factor IX (FIX) or the activated form thereof Factor IXa (FIXa) and optionally Factor X (FX) and the acti...  
WO/2018/144773A1
The present disclosure provides methods of treating diuretic resistance by administering an IL-6 antagonist to patients who require diuresis. In typical embodiments, the patient has heart failure. Optionally, the patient has elevated uri...  
WO/2018/145125A1
The present disclosure provides a coagulation factor VIII (FVIII) mimetic protein. The FVIII mimetic protein comprises (1) a coagulating factor IX (FIX/FIXa) binding domain comprising a first heavy chain variable region (VH1) and a first...  
WO/2018/137701A1
The present invention provides a pharmaceutical composition and a method for treating a cardiovascular disease. Particularly, the present invention provides a CXCR7-targeting method and pharmaceutical composition for treating vascular en...  
WO/2018/139477A1
Provided is a novel therapeutic agent for nephrogenic anemia which is efficacious for ESA resistant patients too. A medicinal composition which comprises an organic nitrate and a pharmacologically acceptable carrier; and a therapeutic ag...  
WO/2018/140425A1
The invention provides novel iso-osmotic or near iso-osmotic formulations of fluorocarbon emulsions that are useful as oxygen therapeutics, for example, for treating sickle cell disease and related diseases and conditions, as well as met...  

Matches 1 - 50 out of 50,819